Labopharm has received a complete response letter from FDA for the new drug application (NDA) submission of its novel formulation of the antidepressant – trazodone. The letter indicates
Boehringer Ingelheim has declared results from the Arten trial at the 5th International AIDS Society conference in Cape Town, South Africa. The study demonstrated non-inferiority regarding efficacy between
Alnylam and Cubist have provided complete data from their phase II study of ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. The phase
The Leukemia & Lymphoma (LLS) and Forma have signed a partnership to accelerate LLS’s pipeline of research projects entering late pre-clinical development. Repotedly, the collaboration will begin with
Nycomed has submitted a New Drug Application (NDA) to the FDA for Daxas, as a once-daily oral treatment for patients with symptomatic COPD. The NDA submission is based
Merck & Co. has reported non-GAAP earnings per share (EPS) for the quarter of $0.83, which excludes $0.09 of restructuring charges and merger-related expenses. Second-quarter GAAP EPS was
Cardax has reported that its lead compound Heptax has shown potential to address metabolic syndrome, including liver and cardiovascular disease as well as diabetes. Heptax is a bioavailable
Stem (SCT) has received a No Objection Letter (NOL) from Health Canada for the modified Regenesis protocol using NTx-265, for a phase IIb clinical trial for the treatment
Mar Cor Purification has launched ready-to-use sporicides, Actril Cold Sterilant, in cleanroom packaging to make it easier to use in cleanroom settings. Actril Cold Sterilant is a surface
For the three months ended 2009, Elan has reported total revenues of $280.9m, compared to $245.6m for the same period, 2008. The operating loss of the company has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.